<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03226483</url>
  </required_header>
  <id_info>
    <org_study_id>2016-638N-MA</org_study_id>
    <nct_id>NCT03226483</nct_id>
  </id_info>
  <brief_title>Intraoperative Radiotherapy After the Resection of Brain Metastases</brief_title>
  <acronym>INTRAMET</acronym>
  <official_title>Intraoperative Radiotherapy After the Resection of Brain Metastases - a Phase II Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsmedizin Mannheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      INTRAMET examines prospectively the effectiveness of an intraoperative radiotherapy immediate&#xD;
      after the surgical resection of brain metastases. Patients won't receive further radiation&#xD;
      therapy of the intraoperatively treated lesion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Brain metastases occur in up to 40% of all patients diagnosed with systemic cancer. Without&#xD;
      adjuvant radiotherapy after resection of space occupying lesions local recurrence rates are&#xD;
      high. That is why guidelines recommend a cavity boosting with x-rays. External beam&#xD;
      radiotherapy can lower the risk of local recurrence but means longer hospitalization,&#xD;
      prolongs the time to systemic salvage therapies and bears risks of radionecrosis and&#xD;
      leucoencephalopathy with neurological and cognitive decline. A solution for this problem&#xD;
      could be onetime intraoperative radiotherapy (IORT) with soft x-rays to sterilize the&#xD;
      resection cavity, which may provide both: freedom from local recurrence fast track salvage&#xD;
      therapy initiation.&#xD;
&#xD;
      INTRAMET is a single institution, open-label, prospective, phase 2 feasibility study for&#xD;
      intraoperative radiotherapy immediately following resection of brain metastases. 50 adult&#xD;
      patients with resectable not dural brain metastases should be treated in surgery after tumor&#xD;
      resection with IORT with 20-30Gy prescribed to the margin of the resection cavity. The&#xD;
      highest dose tolerable to surrounding risk structures (N. opticus, brainstem) should be used.&#xD;
&#xD;
      With this method, the investigators hope to show similar local control rates to postoperative&#xD;
      external beam radiotherapy in line with guideline recommendations with less patient&#xD;
      hospitalization and faster start of rescue therapies which could lead to a favorable overall&#xD;
      outcome and less cognitive side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median local progression-free-survival</measure>
    <time_frame>2 years</time_frame>
    <description>Rate of recurrence of the treated lesion in the brain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall-survival</measure>
    <time_frame>5 years</time_frame>
    <description>Survival differentiated between death due to systemic cancer progress and death due to cerebral progress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to further therapy</measure>
    <time_frame>6 month</time_frame>
    <description>Time to further cancer therapy (e.g. salvage chemotherapy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients cognitive performance</measure>
    <time_frame>5 years</time_frame>
    <description>Neuropsychological battery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients quality of life</measure>
    <time_frame>5 years</time_frame>
    <description>Patient questionary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global progression-free-survival</measure>
    <time_frame>2 years</time_frame>
    <description>Systemic cancer progression-free-survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional progression-free-survival</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free survival concerning other brain metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative radiotherapy caused dose-limiting toxicities</measure>
    <time_frame>6 month after intervention</time_frame>
    <description>Occurrence of wound healing disorders or infection requiring surgical revision, cerebral bleeding or ischemia, radionecrosis requiring surgical intervention</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Intraoperative radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After neurosurgical resection and proven metastasis (frozen section) a local intraoperative radiotherapy with soft energy x-rays is applied to the resection cavity.&#xD;
To perform this an applicator is inserted into the situs in the tightest fit rule. The highest possible dose between 30-20 Gy is chosen depending on nearby risk structures (Optic nerve, brainstem) is prescribed. After radiotherapy the applicator is removed and the surgery will be finished in standard way.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intraoperative Radiotherapy</intervention_name>
    <description>Intraoperative Radiotherapy is performed with a mobile radiation device emitting soft energy x-rays in a spherical way. Different size applicators are available to cover the resection cavity after the tightest fit rule.</description>
    <arm_group_label>Intraoperative radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Karnofsky Performance index ≥ 50%&#xD;
&#xD;
          -  MRI T1 Gadolinium enhancing non-dural resectable lesion&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Adequate birth control&#xD;
&#xD;
          -  Frozen section confirms metastasis&#xD;
&#xD;
          -  Adequate distance to optic nerve and brainstem&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dural lesions or meningeal carcinomatosis&#xD;
&#xD;
          -  Frozen section reveals glioma, lymphoma,small cell lung cancer or germinoma&#xD;
&#xD;
          -  Psychiatric or social condition interfering compliance&#xD;
&#xD;
          -  Contraindication against anesthesia, surgery, MRI and/or Gadolinium&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefanie Brehmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsmedizin Mannheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefanie Brehmer, MD</last_name>
    <phone>+49 621 383 2750</phone>
    <email>stefanie.brehmer@umm.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frank A Giordano, MD</last_name>
    <email>frank.giordano@umm.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefanie Brehmer, MD</last_name>
      <phone>+49 621 383 2750</phone>
      <email>stefanie.brehmer@umm.de</email>
    </contact>
    <contact_backup>
      <last_name>Frank A Giordano, MD</last_name>
      <email>frank.giordano@umm.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stefanie Brehmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank Giordano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsmedizin Mannheim</investigator_affiliation>
    <investigator_full_name>Stefanie Brehmer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Brain Metastases</keyword>
  <keyword>Intraoperative Radiotherapy</keyword>
  <keyword>Neurosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

